{"id":"acalabrutinib-treatment-d","safety":{"commonSideEffects":[{"rate":"22%","effect":"Headache"},{"rate":"21%","effect":"Diarrhea"},{"rate":"20%","effect":"Nausea"},{"rate":"19%","effect":"Fatigue"},{"rate":"18%","effect":"Muscle pain"}]},"_chembl":{"chemblId":"CHEMBL4747506","moleculeType":"Unknown","molecularWeight":"465.52"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Acalabrutinib is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), which plays a key role in the signaling pathways of B cells.","oneSentence":"BTK inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:52:08.129Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT04115631","phase":"PHASE2","title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-12-13","conditions":"Liver Lymphoma, Mantle Cell Lymphoma","enrollment":360},{"nctId":"NCT04855695","phase":"PHASE1, PHASE2","title":"Avo In R/R And Previously Untreated MCL","status":"RECRUITING","sponsor":"Austin I Kim","startDate":"2021-07-02","conditions":"Mantle Cell Lymphoma, Refractory Lymphoma","enrollment":72},{"nctId":"NCT04604067","phase":"PHASE2","title":"Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2021-06-25","conditions":"Diffuse Large B-cell Lymphoma","enrollment":260},{"nctId":"NCT03162536","phase":"PHASE1, PHASE2","title":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2017-06-26","conditions":"Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia","enrollment":190},{"nctId":"NCT04419389","phase":"PHASE1, PHASE2","title":"APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)","status":"TERMINATED","sponsor":"Aprea Therapeutics","startDate":"2021-03-02","conditions":"Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":1},{"nctId":"NCT04783415","phase":"PHASE2","title":"Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-03-26","conditions":"Mantle Cell Lymphoma","enrollment":12},{"nctId":"NCT04626791","phase":"PHASE2","title":"Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2021-08-03","conditions":"Mantle Cell Lymphoma","enrollment":45},{"nctId":"NCT04867980","phase":"PHASE1","title":"A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2016-04-01","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT04488016","phase":"PHASE1","title":"A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-06-24","conditions":"Bioavailability, B-cell Lymphoid Cancer","enrollment":54},{"nctId":"NCT04564040","phase":"PHASE1","title":"A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-10-12","conditions":"Mantle Cell Lymphoma, COVID-19","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AT"],"phase":"phase_1","status":"active","brandName":"Acalabrutinib Treatment D","genericName":"Acalabrutinib Treatment D","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BTK inhibitor Used for Chronic lymphocytic leukemia, Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}